Is MOTS-c Legal in Wisconsin? How to Access It Legally
HealthRX.com
MOTS-c has no approved legal path in Wisconsin yet
Key numbers
- 5 mgNominated product strength for the pharmacy bulks list, as subcutaneous injection (10 mg also nominated)Source: fda.gov, as cited Nov 7, 2026
- 970 daysMedian lifespan in a mouse study after late-life MOTS-c dosing, up from 912 days (animal data only)Source: fda.gov, as cited Nov 7, 2026
- 15 mg/kgMouse dose in a late-life lifespan study, given three times weekly (not a human dose)Source: fda.gov, as cited Nov 7, 2026
See the public record for MOTS-c
At a glance
- FDA approval / None. MOTS-c is not a component of any approved drug [1]
- FDA bulks list / Not listed, and in none of the three interim categories [2][9]
- FDA staff position / Recommended against adding it, July 2026 [1]
- Advisory committee / Voted on 23 July 2026 to add it; advice only [5][3]
- HHS, October 2026 / Draft non-enforcement policy names MOTS-c [3][4]
- Wisconsin / Chapter 450 covers pharmacy licensing and practice rules [6]
- Products nominated / 5 mg and 10 mg subcutaneous injections [1]
- Sport / WADA prohibits it at all times [7]
What is MOTS-c's federal legal status?
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 by Lee and colleagues in Cell Metabolism [8]. It is not an FDA-approved drug and is not a component of one. FDA's July 2026 review found no USP or National Formulary monograph for it, no listing in the European or Japanese pharmacopeias, and no product authorized by the European Medicines Agency [1].
The free base and the acetate salt are treated by FDA as different bulk substances, and 'MOTS-c' is a common name rather than an official drug name [1].
Can a pharmacy compound MOTS-c?
FDA's rules for state-licensed pharmacies and physicians allow three routes to a bulk drug substance: it complies with a USP or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on FDA's list of bulk drug substances that can be used in compounding [2]. MOTS-c meets none of those conditions, and it appears in none of the three categories in FDA's interim policy, so the category 1 policy, under which FDA says it does not intend to act against compounders, does not cover it [9][2].
MOTS-c sits in FDA's 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them. FDA's stated concerns are that it 'has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration', that important safety information is missing, and that injectable peptides may pose immunogenicity risk from aggregation and peptide-related impurities. Removal from category 2 was not a finding that it is safe [10].
In July 2026, FDA staff proposed that neither the free base nor the acetate be added to the pharmacy bulks list, citing poor characterization (inconsistent naming, no impurity, aggregate or endotoxin data), unknown use in compounding, no animal toxicity studies, and the existence of approved treatments for obesity and osteoporosis, two of the nominated uses [1].
Did the July 2026 advisory committee vote change that?
FDA's Pharmacy Compounding Advisory Committee reviewed MOTS-c on July 23, 2026 and voted in favor of adding it to the bulks list, against FDA staff's recommendation [5][3]. That is advice only and not binding. MOTS-c is not on the list, and adding it takes formal rulemaking [3].
What does the HHS draft policy say?
HHS filed a draft enforcement-discretion policy for certain peptides on October 28, 2026 (Federal Register document 2026-22192, publication scheduled for October 30, 2026, with comments due two weeks after publication). It names MOTS-c among six peptides and covers MOTS-c acetate given by subcutaneous or intramuscular injection. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the policy's conditions are met, for example a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [3][4]
The same notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example if a safety signal or product quality issue arises [3]. It is not an FDA approval and does not add MOTS-c to any list [3]. Compounded drugs are not FDA-approved; FDA does not review their safety, effectiveness or quality before marketing [3].
What does Wisconsin law add?
Wisconsin's pharmacy statute, Chapter 450, creates the Pharmacy Examining Board and covers licensure of pharmacists, in-state pharmacies, out-of-state pharmacies and manufacturers, along with rules on prescription drugs, labeling and disciplinary proceedings [6]. The federal bulk-substance conditions described above are the ones FDA applies to state-licensed pharmacies and physicians that compound [2].
Is there any human data on MOTS-c?
FDA found no published study in which MOTS-c, compounded or not, was given to a human, so its safety in humans is unknown; searches of its adverse-event database through March 9, 2025 retrieved no MOTS-c reports [1]. The pharmacology comes from cells and mice. In mice, injected MOTS-c reduced weight gain on a high-fat diet, with about 20% lower body weight after 8 weeks at 0.5 mg/kg/day intraperitoneally. In one study a late-life schedule (15 mg/kg three times weekly from 23.5 months of age) lengthened median lifespan from 912 to 970 days [1][11].
FDA found no pharmacokinetic data in humans or live animals; the only kinetic observation is that MOTS-c is quickly broken down in human blood in vitro, which raises the question whether injecting it can produce active levels in people [1]. There is no approved dose and no human dosing study, and the rodent doses cannot be converted into human doses [1].
Is MOTS-c prohibited in sport?
WADA names MOTS-c in S4.4.1, the metabolic modulators section covering AMPK activators, and prohibits it at all times, in and out of competition. It is on the 2026 List and stays on the 2027 List; S4.4 substances are non-Specified Substances [7][12].
How is MOTS-c actually sold, and what does that mean for a Wisconsin patient?
FDA notes that MOTS-c is marketed on websites alone and in combinations, including an 'IV cocktail' offered by a wellness clinic, for metabolism, weight loss, glucose control, performance and anti-aging, and that no outsourcing facility reported compounding it between January 2017 and December 2025 [1]. The products nominated for the bulks list were 5 mg and 10 mg subcutaneous injections [1].
For a Wisconsin patient, there is no FDA-approved MOTS-c product, and no listing that would let a pharmacy compound it as a matter of course [1][2]. A prescription from a Wisconsin-licensed prescriber does not itself put a bulk substance on FDA's list [2].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
What people on Reddit report
One long post from a community member summarizing the FDA compounding review. No first-hand patient accounts of obtaining MOTS-c.
If the FDA moves this July batch onto the 503A list, it means that a compounding pharmacy could legally prepare it for you with a prescription, under real pharmacy quality controls.Read the source discussion
However, this classification does not mean FDA approval. This is a far higher bar that needs research and safety trials.Read the source discussion
Questions worth asking
Frequently asked questions
Is MOTS-c legal in Wisconsin?
Can a Wisconsin doctor prescribe MOTS-c?
Did the July 2026 advisory committee vote make MOTS-c legal?
Does the HHS draft policy make MOTS-c legal?
What are the safety concerns with injectable MOTS-c?
Can I use MOTS-c if I compete in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Can I get a prescription for MOTS-c?
Not through the normal federal route. A Wisconsin-licensed prescriber can write a prescription, but that does not put MOTS-c on FDA's list of bulk drug substances, and it meets none of the three conditions for legal bulk use. HHS's October 2026 draft policy describes when it does not intend to take enforcement action for MOTS-c acetate injections, but the notice says it is not binding and is not an approval.
Where can I purchase MOTS-c?
MOTS-c is marketed on websites alone and in combinations, including an 'IV cocktail' offered by a wellness clinic, according to FDA. There is no FDA-approved MOTS-c product, so no sale is backed by FDA approval.
Is MOTS-c legal now?
No, not under federal approval. MOTS-c is not FDA-approved and is not on FDA's list of bulk drug substances that pharmacies may compound. The July 2026 advisory committee vote was advice only, and HHS's October 2026 draft policy is non-binding and is not an approval or a listing.
Are there any human trials with Mots-C?
No published study has given MOTS-c to a human, according to FDA, so its safety in humans is unknown. There is no approved dose and no human dosing study, and the rodent doses cannot be converted into human doses. The pharmacology comes from cells and mice.
References
Show all 13 referencesHide references
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- Wisconsin Legislature: Chapter 450.
- World Anti-Doping Agency.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- World Anti-Doping Agency.
- Reddit participants. The FDA is reviewing 7 peptides on July 23–24. Here's what's being decided. (r/PeptideTides). Accessed 2026-11-11.